Johnson & Johnson MedTech Acquires Laminar, Inc.
2023年11月30日 · Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond. Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the ...
Irvine, CA – February 27, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech i, announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study ...
J&J begins enrolling patients in Laminar LAA pivotal trial
2024年2月28日 · Johnson & Johnson has started patient enrollment in a pivotal trial to evaluate its Laminar left atrial appendage (LAA) elimination device for reducing stroke risk due to blood clot formation in the heart, the company said Tuesday.
J&J heats up LAA closure competition with $400M Laminar buy
2023年11月30日 · Competition in the left atrial appendage (LAA) closure market intensified this week, once again, with Johnson & Johnson’s acquisition of Laminar, a Santa Rosa, California-based company that is developing a new approach to eliminate the LAA.
Johnson & Johnson enters LAA device space with Laminar buy
2023年11月30日 · Johnson & Johnson MedTech (NYSE: JNJ) + announced today that it completed the acquisition of left atrial appendage (LAA) device maker Laminar.
强生 Laminar左心耳封堵器 (LAAO) IDE研究启动在 …
2023年12月20日 · 强生 Laminar左心耳封堵器 (LAAO) IDE研究启动在即（NCT06168942）自2023年11月30日强生宣布收购Laminar, Inc.后，其IDE临床研究正在有序推进中，12月5日Laminar, Inc.就在clinicaltrials.gov进行了IDE临床研究登记，从登记的信息来看，IDE研究将于24年2月份正式开始，主要临床终点 ...
Laminar, Inc. Acquired by Johnson & Johnson Medtech for $400 …
2023年11月30日 · Laminar will join Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment. More than 38 million people worldwide currently live with AFib, a...
Johnson & Johnson MedTech Acquires Laminar, Inc. | Johnson
2023年11月30日 · You should view the News section and the most recent SEC Filings in the Investor section in order to receive the most current information made available by Johnson & Johnson Services, Inc. Contact us with any questions or search this site for more information.
Johnson & Johnson MedTech Acquires Laminar, Inc.
2023年11月30日 · Johnson & Johnson MedTech has acquired Laminar, Inc., a company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).
02.13.25 J&J MedTech Virtual Peer to Peer: NUVISION™ …
02.13.25 J&J MedTech Virtual Peer to Peer: NUVISION™ Ultrasound Catheter for LAAO Discover the Value of 4D ICE for LAAO